Levetiracetam well-tolerated for Alzheimer’s disease
Oct 01, 2021
It does not improve primary outcome but did improve performance on certain cognitive tasks in those with epileptiform activity.
High BP visit-to-visit variability linked to dementia risk in late life
Oct 31, 2023
Higher blood pressure variability was not associated with higher lifetime dementia risk at age 60, 70 or 80 years.
Blood tests and phone apps: The future of diagnosing Alzheimer’s?
By
Lois A. Bowers
Apr 08, 2019
Last week in a blog post, Bill Gates shared some exciting ways that Alzheimer’s disease might be diagnosed in the future.
Sleep-disordered breathing linked to medial temporal lobe atrophy in seniors
Jun 02, 2023
Higher sleep apnea severity was related to lower medial temporal lobe subregion volumes in amyloid-positive, but not amyloid-negative, individuals.
Medicare monthly premiums to drop for seniors
Sep 28, 2022
The fee cuts come at the same time as seniors receive a Social Security cost-of-living increase for 2023 of up to 9 or 10%.
Pricey Alzheimer drug drives spike in Medicare B premium: Officials
Nov 15, 2021
New premium will be $170.10 a month, and the $21.60 boost is the biggest increase ever in dollar amount, but not in percentage terms
Composite inflammatory biomarker linked to dementia risk
Jul 21, 2023
Small but significant associations were seen between elevated biomarker levels and worsened cognitive performance.
Distance to neurologist, PCP may explain Alzheimer’s disease disparities
Apr 05, 2024
Non-Hispanic American Indian and/or Alaska Native and Hispanic decedents have to travel further to neurologist than non-Hispanic whites.
Senators ask president for more Alzheimer’s funding
By
Lois A. Bowers
Feb 02, 2018
A group of 14 senators led by Sen. Susan Collins (R-ME), founder and co-chair of the Senate Alzheimer’s Task Force, and Sen. Amy Klobuchar (D-MN) on Wednesday asked President Trump to boost funding...
Donanemab slows clinical progression in early Alzheimer’s disease
Jul 17, 2023
The drug slows clinical progression at 76 weeks for those with low/medium tau and the combined low/medium and high tau pathology population.